{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=5",
    "query": {
      "intervention": "Cancer Immunotherapy",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 1781,
    "total_pages": 179,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cancer+Immunotherapy&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:47:25.317Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00254904",
      "title": "Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "PF-3512676",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine + Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 839,
      "start_date": "2005-11",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Saint Joseph, Michigan + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Saint Joseph",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00254904"
    },
    {
      "nct_id": "NCT05973487",
      "title": "A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer",
        "Cervical Cancer",
        "Non-small Cell Carcinoma",
        "Melanoma",
        "Ovarian Cancer",
        "Anogenital Cancers",
        "HPV - Anogenital Human Papilloma Virus Infection",
        "HPV-Related Cervical Carcinoma",
        "HPV-Related Carcinoma",
        "HPV-Related Squamous Cell Carcinoma",
        "HPV-Related Malignancy",
        "HPV-Related Adenocarcinoma",
        "HPV Positive Oropharyngeal Squamous Cell Carcinoma",
        "HPV-Related Adenosquamous Carcinoma",
        "HPV-Associated Vaginal Adenocarcinoma",
        "HPV-Related Endocervical Adenocarcinoma",
        "HPV-Related Anal Squamous Cell Carcinoma",
        "HPV-Related Verrucous Carcinoma",
        "HPV-Related Penile Squamous Cell Carcinoma",
        "HPV-Related Vulvar Squamous Cell Carcinoma",
        "HPV Positive Rectal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "TSC-204-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-C0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-200-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-204-A0101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-201-B0702",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-C0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-200-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-203-A0201 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-204-A0101 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TSC-201-B0702 + TSC-202-A0201",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TScan Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 840,
      "start_date": "2024-05-06",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-17",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 21,
      "location_summary": "Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05973487"
    },
    {
      "nct_id": "NCT03445663",
      "title": "Study Evaluating AMG 424 in Subjects With Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/ Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AMG 424",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2018-07-31",
      "completion_date": "2020-06-19",
      "has_results": false,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Charlotte, North Carolina • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03445663"
    },
    {
      "nct_id": "NCT03315871",
      "title": "Combination Immunotherapy in Biochemically Recurrent Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Antigen direct immunotherapy: PROSTVAC-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antigen direct immunotherapy: PROSTVAC-F",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MSB0011359C (M7824)",
          "type": "DRUG"
        },
        {
          "name": "Antigen direct immunotherapy: CV301",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CT scan of chest",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT scan of abdomen/pelvis",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PSMA",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2018-03-20",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2025-06-19",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315871"
    },
    {
      "nct_id": "NCT00179309",
      "title": "Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "PANVAC-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PANVAC-F",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 48,
      "start_date": "2005-09",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2014-07-15",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179309"
    },
    {
      "nct_id": "NCT02574533",
      "title": "Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma Recurrent",
        "Malignant Melanoma",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vigil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2015-10",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-09-27",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 3,
      "location_summary": "Abilene, Texas • Dallas, Texas • Spokane, Washington",
      "locations": [
        {
          "city": "Abilene",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574533"
    },
    {
      "nct_id": "NCT02036918",
      "title": "Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sipuleucel-T",
          "type": "DRUG"
        },
        {
          "name": "Lymph Node Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2019-02-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036918"
    },
    {
      "nct_id": "NCT02405585",
      "title": "Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Pancreatic Carcinoma Non-resectable"
      ],
      "interventions": [
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Algenpantucel-L Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SBRT",
          "type": "RADIATION"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2015-04",
      "completion_date": "2016-07-30",
      "has_results": false,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 4,
      "location_summary": "Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Burlington",
          "state": "Massachusetts"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02405585"
    },
    {
      "nct_id": "NCT07443020",
      "title": "Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Pleural Effusion",
        "Malignant Mesothelioma",
        "Pleural Effusion, Malignant",
        "Metastasis to Pleura"
      ],
      "interventions": [
        {
          "name": "locally manufactured adoptive cellular therapy (ACT) product",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2 (IL-2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-05",
      "completion_date": "2038-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07443020"
    },
    {
      "nct_id": "NCT01754376",
      "title": "Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2013-01",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-11-21T01:47:25.317Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01754376"
    }
  ]
}